Clinical trials: Hepato-cellular Carcinoma
Hepato Cellular Carcinoma (HCC), Hepatobiliary Cancers
Effect and Mechanism of ALPPS Operation on Liver Regeneration
Hepatobiliary malignancies-principally hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA)-are highly aggressive and often diagnosed at advanced stages.
- Conditions
- Hepato Cellular Carcinoma (HCC), Hepatobiliary Cancers, Liver Cancer, Liver Regeneration
- Trial name
- NCT07142213
- Testing
- ALPPS
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Haitao Zhao, MD
Liver Carcinoma, Liver Transplant
Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence
This is a retrospective study of single-center cohorts that involves patients with HCC who underwent liver transplantation between January 2016 and 2021, who received livers preserved with Hypothermic Oxygenated Perfusion (HOPE)…
- Conditions
- Liver Carcinoma, Liver Transplant, Tumor Recurrence, Hepato Cellular Carcinoma (HCC)
- Trial name
- NCT06720675
- Testing
- Hypothermic Oxygented Perfusion, Static Cold Storage
- Where
- Italy
- Volunteers
- 237 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepato Cellular Carcinoma (HCC)
First Line Hepato Cellular Carcinoma (HCC)
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
- Trial name
- BRISK FL (NCT00858871)
- Testing
- Brivanib, Sorafenib
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 1,714 people
- Sponsor
- Bristol-Myers Squibb
Hepato Cellular Carcinoma (HCC)
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure.
- Trial name
- HCC-SIGHT (NCT07328009)
- Testing
- Lenvatinib, Regorafenib (BAY 73-4506), Tislelizumab+TKI
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma (HCC)
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
This Phase I/II trial aims to evaluate the pharmacokinetics, efficacy, and safety of tirapazamine administered via hepatic artery injection followed by TACE in patients with intermediate-stage HCC.
- Trial name
- NCT06848556
- Testing
- tirapazamine, Transarterial Embolization, TACE
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Hepato Cellular Carcinoma (HCC)
Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab
The purpose of this study is to evaluate whether fecal microbiota transplantation (FMT), when administered in combination with atezolizumab and bevacizumab, can improve treatment response in participants with hepatocellular…
- Trial name
- NCT07276100
- Testing
- Fecal microbiota transplantation (FMT), Atezolizumab & Bevacizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepato Cellular Carcinoma (HCC)
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
This is a single-arm, phase II clinical trial evaluating the safety and efficacy of PD-L1 antibody combined with bevacizumab and hepatic arterial infusion chemotherapy (HAIC) for patients with advanced unresectable hepatocellular…
- Trial name
- NCT06742424
- Testing
- PD-L1 antibody, Bevacizumab, HAIC-FOLFOX
- Where
- China
- Volunteers
- 36 people
- Sponsor
- West China Hospital
Hepato Cellular Carcinoma (HCC)
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
This study will evaluate the efficacy and safety of therapy perioperative treatment with HAIC combined with donafenib and sintilimab (group A)/ donafenib combined with sintilimab (group B) compared with direct surgery (group C)…
- Trial name
- NCT06812039
- Testing
- HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery
- Where
- 3 sites in China
- Volunteers
- 165 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma
Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE
Conventional transarterial chemoembolization with Doxorubicin (c-TACE) is the gold standard treatment for Hepato Cellular Carcinoma (HCC) stage B (BCLC) / stages A and B (Child-Pugh).
- Trial name
- CineDoxo (NCT03706157)
- Testing
- Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media, Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Strasbourg, France
Hepato Cellular Carcinoma (HCC), Portal Vein Tumour Thrombosis
PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma…
- Trial name
- NCT06960954
- Testing
- Prothrombin induced by vitamin K absence II (PIVKA-II)
- Where
- Egypt
- Volunteers
- 116 people
- Sponsor
- Tanta University
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing.
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07716345
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepato Cellular Carcinoma (HCC)
Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma
The goal of this prospective cohort study is to evaluate the role of transient elastography (Fibroscan) in predicting the response of immunotherapy in advanced Hepatocellular carcinoma (HCC) patients.
- Trial name
- NCT06960863
- Testing
- fibroscan
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Tanta University
Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor
An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC
The goal of this clinical trial is to evaluate whether giving a single dose of Nivolumab (Opdivo®) before curative surgery for patients with resectable liver cancer can activate the body's immune response against the cancer and…
- Conditions
- Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor, Neoadjuvant Therapy
- Trial name
- NCT07902258
- Testing
- Nivolumab
- Where
- 3 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Hepato Cellular Carcinoma, Cirrhosis
PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)
Chronic liver diseases affect 1.5 billion people worldwide and can lead to cirrhosis and hepatocellular carcinoma (HCC), which ranks as the third leading cause of cancer-related mortality globally.
- Conditions
- Hepato Cellular Carcinoma, Cirrhosis, Autonomic Nervous System, Central Nervous System
- Trial name
- PSYLIVER-PILOT (NCT07393074)
- Testing
- Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation., Self-administered questionnaires to assess psycho-behavioral traits, Analysis of nocturnal cardiac activity (at home): electrocardiographic (ECG) recording of heart activity during one night.
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Hepato Cellular Carcinoma (HCC)
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07536789
- Testing
- MRG003
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma (HCC), Hand Foot Skin Syndrome
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
SHIELD is a single-center, open-label, single-arm prospective study designed to evaluate whether pre-emptive topical indomethacin can reduce sorafenib-associated hand-foot syndrome (HFS) in patients with advanced hepatocellular…
- Trial name
- NCT07560566
- Testing
- Topical Indomethacin
- Where
- Taiwan
- Volunteers
- 39 people
- Sponsor
- National Taiwan University Hospital